Loading clinical trials...
Loading clinical trials...
Discover 23,476 clinical trials near Baltimore, Maryland. Find research studies in your area.
Showing 5661-5680 of 23,476 trials
NCT07075653
The goal of this observational study is to learn what affects a person's openness to adopting a vegetarian diet in urban community members with chronic disease. The main questions it aims to answer are: How open are individuals to adopting a vegetarian diet? What are the barriers to adopting a vegetarian diet? Researchers will compare Black and White individuals to see if there are differences. Participants will be asked to fill out a survey about their openness to going vegetarian as well as barriers to going vegetarian such as perceived stigma, tastiness, financial cost, convenience, familiarity, and healthfulness.
NCT01781728
The investigators are looking to see if a certain dose of stereotactic body radiation therapy (SBRT) may be a viable treatment option for recurrent or residual pancreatic or periampullary adenocarcinoma.
NCT05127954
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate long term safety and tolerability of ubrogepant in the acute treatment of migraine in pediatric participants. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Pediatric participants (aged 6-17 years) with a history of migraine will be enrolled. Participants who completed the lead-in Study 3110-305-002, as well as those who were placebo responders and screen failed, will be eligible to enroll into this study. Around 1200 participants will be enrolled in the study at approximately 120 sites in the United States. Participants may receive ubrogepant oral tables to treat up to 8 migraine attacks of any intensity per month. There will be an option to take a second dose of study intervention (identical to initial dose), or rescue medication, starting 2 hours after the initial dose. The study duration will be up to 54 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The safety and tolerability of the treatment will be checked by medical assessments, blood tests, checking for adverse events and completing questionnaires.